Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Prenat Diagn ; 34(2): 159-62, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24226752

ABSTRACT

OBJECTIVES: The objective of this article is to determine whether there were differences in first trimester serum analytes between cases of placenta previa with and without accreta. METHODS: Cases of placenta previa in which the patient had first trimester aneuploidy screening were identified. Pregnancy-associated plasma protein A (PAPP-A) and free beta human chorionic gonadotropin (fbhCG) MoMs were compared with those with an accreta. Accreta cases were also compared with published distributions to determine significance and to develop likelihood ratios based on MoM values. RESULTS: Eighty-two cases of previa were identified, including 16 with a histological diagnosis of placenta accreta. The median PAPP-A MoM of 1.68 in accreta was significantly greater than that of 0.98 in non-accreta (P = 0.002). For fbhCG, the median MoM was 1.00 and 1.01 in accreta and non-accreta, respectively. Of the 16 patients with accreta, 14 (87.5%, 95% confidence interval: [61.6%, 98.4%]) had PAPP-A MoM above 1.0. Six of 16 (37.5%) accreta cases were above the 90th percentile of the unaffected distribution. The likelihood ratios for accreta were 0.5, 2.0, and 3.0. PAPP-A MoMs were 0.19, 2.11, and 4.27, respectively. CONCLUSIONS: First trimester PAPP-A levels may be useful in identifying pregnancies at high risk for placenta accreta. Larger studies could incorporate both clinical and biochemical data into a risk algorithm.


Subject(s)
Chorionic Gonadotropin, beta Subunit, Human/metabolism , Placenta Accreta/metabolism , Pregnancy-Associated Plasma Protein-A/metabolism , Adult , Biomarkers/metabolism , Cohort Studies , Female , Humans , Pregnancy , Pregnancy Trimester, First/metabolism , Retrospective Studies , Young Adult
2.
Br J Anaesth ; 103(2): 268-74, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19541679

ABSTRACT

BACKGROUND: Caudal block is a common technique for paediatric analgesia but with the disadvantage of short duration of action after single injection. Caudal dexmedetomidine and clonidine could offer significant analgesic benefits. We compared the analgesic effects and side-effects of dexmedetomidine and clonidine added to bupivacaine in paediatric patients undergoing lower abdominal surgeries. METHODS: Sixty patients (6 months to 6 yr) were evenly and randomly assigned into three groups in a double-blinded manner. After sevoflurane in oxygen anaesthesia, each patient received a single caudal dose of bupivacaine 0.25% (1 ml kg(-1)) combined with either dexmedetomidine 2 microg kg(-1) in normal saline 1 ml, clonidine 2 microg kg(-1) in normal saline 1 ml, or corresponding volume of normal saline according to group assignment. Haemodynamic variables, end-tidal sevoflurane, and emergence time were monitored. Postoperative analgesia, use of analgesics, and side-effects were assessed during the first 24 h. RESULTS: Addition of dexmedetomidine or clonidine to caudal bupivacaine significantly promoted analgesia time [median (95% confidence interval, CI): 16 (14-18) and 12 (3-21) h, respectively] than the use of bupivacaine alone [median (95% CI): 5 (4-6) h] with P<0.001. However, there was no statistically significant difference between dexmedetomidine and clonidine as regards the analgesia time (P=0.796). No significant difference was observed in incidence of haemodynamic changes or side-effects. CONCLUSIONS: Addition of dexmedetomidine or clonidine to caudal bupivacaine significantly promoted analgesia in children undergoing lower abdominal surgeries with no significant advantage of dexmedetomidine over clonidine and without an increase in incidence of side-effects.


Subject(s)
Analgesia, Epidural/methods , Analgesics, Non-Narcotic/administration & dosage , Clonidine/administration & dosage , Dexmedetomidine/administration & dosage , Pain, Postoperative/prevention & control , Abdomen/surgery , Analgesics, Non-Narcotic/adverse effects , Anesthesia, Inhalation/methods , Anesthetics, Local/administration & dosage , Bupivacaine/administration & dosage , Child , Child, Preschool , Clonidine/adverse effects , Dexmedetomidine/adverse effects , Double-Blind Method , Drug Administration Schedule , Female , Humans , Infant , Male , Pain Measurement/methods
3.
Chemotherapy ; 37(1): 66-9, 1991.
Article in English | MEDLINE | ID: mdl-2013244

ABSTRACT

In the last 2 years, 50 patients who underwent elective colorectal surgery were prospectively studied about antibiotic prophylaxis. Two groups of 25 patients each were randomly selected. Both received: (a) a colic preparation: hypactic drugs and two enemas during the day before surgery and (b) metronidazole 0.5 g plus neomycin 1 g per 8 h orally for 1 day before surgery. Every group also received: group A, metronidazole 0.5 g plus amikacin 500 mg i.v. 2 h before surgery and the same doses per 8 or 12 h, respectively, for 2 days postoperatively; group B, ornidazole 1 g by intravenous infusion plus ceftriaxone 2 g i.v. 2 h before surgery and the same doses of the drugs per 24 h for 2 days postoperatively. Wound infection occurred in 1 case of group A versus 2 cases of group B (p greater than 0.25). Ornidazole plus ceftriaxone prophylactic antibiotic therapy is therefore as effective as a classic therapy (metronidazole plus amikacin) and constitutes an alternative choice for patients undergoing elective colorectal surgery, because the simple manner of its administration (once per 24 h) is resulting in cost saving due to gained nursing time.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacterial Infections/prevention & control , Premedication , Aged , Amikacin/administration & dosage , Amikacin/therapeutic use , Anti-Bacterial Agents/administration & dosage , Ceftriaxone/administration & dosage , Ceftriaxone/therapeutic use , Colorectal Neoplasms/surgery , Costs and Cost Analysis , Female , Humans , Infusions, Intravenous , Male , Metronidazole/administration & dosage , Metronidazole/therapeutic use , Middle Aged , Ornidazole/administration & dosage , Ornidazole/therapeutic use , Prospective Studies
4.
Acta Chir Scand ; 156(11-12): 771-4, 1990.
Article in English | MEDLINE | ID: mdl-2075774

ABSTRACT

The effect of trimetazidine (an antianginal drug that acts as a scavenger of oxygen radicals) in the prevention of peritoneal adhesions induced by complete vascular obstruction of an ileal segment for 30 minutes followed by reperfusion was investigated in rats. Group A (n = 20) acted as controls. Group B (n = 20) received trimetazidine intravenously in a dose of 2.5 mg/kg 30 minutes before the induction of ischaemia. Group C (n = 20) received the same dose of trimetazidine for 5 days before the experiment, twice a day intraperitoneally, and also intravenously 30 minutes before the induction of ischaemia. Group D (n = 20) received the same dose of trimetazidine intravenously immediately after reperfusion had started. Ten days later adhesions had developed in 90% of the animals of group A, 40% of those in group B (p less than 0.001), 5% of those in group C (p less than 0.001), and 60% of those in group D (p less than 0.05). The severity of adhesions was significantly less in the treated groups than in the control animals. Release of creatine phosphokinase during ischaemia and reperfusion significantly increase in groups A, B, and D. These results suggest that trimetazidine reduces the incidence and severity of peritoneal adhesion formation induced by ileal ischaemia and reperfusion, treatment before induction of ischaemia gave better results than treatment given afterwards.


Subject(s)
Peritoneal Diseases/prevention & control , Trimetazidine/therapeutic use , Animals , Creatine Kinase/blood , Female , Ileum/blood supply , Ischemia/complications , Peritoneal Diseases/blood , Peritoneal Diseases/etiology , Rats , Rats, Inbred Strains , Reperfusion Injury/complications , Tissue Adhesions/blood , Tissue Adhesions/etiology , Tissue Adhesions/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL